

Adverse Drug Reactions - Part II



Course Author(s): Kristin A. Williams, DDS, MPH; M. Louay Taifour, BDS, DMD; Michael A. Huber, DDS

CE Credits: 2 hours

Intended Audience: Dentists, Dental Hygienists, Dental Assistants, Dental Students, Dental Hygiene Students, Dental Assisting Students

Date Course Online: 08/01/2017

Last Revision Date: 02/27/2023

Course Expiration Date: 02/26/2026

Cost: Free

Method: Self-instructional

AGD Subject Code(s): 10

Online Course: www.dentalcare.com/en-us/ce-courses/ce537

Disclaimer: Participants must always be aware of the hazards of using limited knowledge in integrating new techniques or procedures into their practice. Only sound evidence-based dentistry should be used in patient therapy.

Conflict of Interest Disclosure Statement

- The authors report no conflicts of interest associated with this course.

Introduction

This course discusses common immune-mediated and idiosyncratic adverse drug reactions (ADRs) related to the top 200 drugs dispensed by U.S. community pharmacies in 2008, and less commonly noted ADRs affecting oral tissues. In addition, uncommon, time-related (delayed), usually dose-related ADRs, i.e., carcinogenesis and teratogenesis, and some secondary ADRs are presented.

Please note this is Part II of a two-part series. [Adverse Drug Reactions - Part I](#) discusses common "on-target," "off-target," and (3) cytotoxic reactions related to the top 200 drugs dispensed by U.S. community pharmacies, and less common ADRs that relate to dental therapeutics and/or manifest in the head and neck area.

Course Contents

- Overview
- Learning Objectives
- Introduction
- Immune-mediated Mechanisms of ADRs
- Mechanisms of Idiosyncratic ADRs
- Mechanisms of Oncogenic ADRs
- Mechanisms of Teratogenic ADRs
- Clinical Manifestations of ADRs
 - ADRs Affecting Skin (Mucosa) and Appendages
 - Hypersensitivity-related ADRs
 - Idiosyncratic ADRs
 - Primary Oncogenesis-related ADRs
 - Teratogenesis-related ADRs
 - Secondary ADRs Related to Therapeutic Immunosuppression
 - Withdrawal Syndrome
- Preventing ADRs
- Diagnosing ADRs
- Reporting ADRs
- Summary
- Course Test
- References
- About the Authors

Overview

This course discusses common immune-mediated and idiosyncratic adverse drug reactions (ADRs) related to the top 200 drugs dispensed by U.S. community pharmacies in 2008, and less commonly noted ADRs affecting oral tissues. In addition, uncommon, time-related (delayed), usually dose-related ADRs, i.e., carcinogenesis and teratogenesis, and some secondary ADRs are presented.

Learning Objectives

Upon completion of this course, the dental professional should be able to:

- Discuss in general terms the mechanisms of immune-mediated, idiosyncratic, oncogenic, teratogenic and secondary ADRs.
- Discuss the spectrum of potential immune-mediated, idiosyncratic, oncogenic, teratogenic and secondary ADRs.
- Discuss issues related to preventing, diagnosing, and reporting ADRs.

Introduction

Drugs seldom exert their beneficial effects without also causing one or more **adverse**

drug reactions (ADRs). Major mechanisms of ADRs include (1) “on-target” adverse reactions, (2) “off-target” adverse reactions, (3) cytotoxic reactions, (4) immune-mediated reactions, and (5) idiosyncratic reactions.¹ In Adverse Drug Reactions – Part I, the discussion focused on mechanisms (1), (2), and (3) and related common ADRs that can occur with therapeutic doses of drugs in the top 200 dispensed by U.S. community pharmacies in 2008.²

In Adverse Drug Reactions – Part II, the discussion is extended to mechanisms (4) immune-mediated reactions and (5) idiosyncratic reactions, and related common ADRs that occur with drugs in the top 200 dispensed by U.S. community pharmacies in 2008, and to less commonly noted ADRs affecting oral tissues. In addition, a brief discussion of the mechanisms of uncommon, time-related (delayed), and usually dose-related ADRs, i.e., carcinogenesis and teratogenesis, and some secondary ADRs are presented.

Immune-mediated Mechanisms of ADRs

There are three major categories of ADRs related to the immune system: immunotoxicity, autoimmune reactions, and hypersensitivity or allergic reactions.¹ **Immunotoxicity** may be the specific intent of therapy, e.g., when monoclonal antibodies target specific B cells. Alternatively, it may occur as an ADR to therapy when cytotoxic agents designed to kill malignant cells also damage normal cells in the bone marrow and lymphoid tissues. Immunotoxicity may also result in secondary ADRs, e.g., infections and oncogenesis.

Drugs can also initiate **autoimmune reactions** resulting in a person’s immune system attacking his/her own cells. For example, a drug may elicit an antibody response to Rh factors on red blood cells (RBCs) causing hemolytic anemia; or induce an antibody response to myeloperoxidase or DNA causing a lupus-like syndrome; or directly cause mast cell degranulation resulting in urticarial lesions; or cause blistering lesions of the skin and mucous membranes, e.g., erythema multiforme or Stevens-Johnson syndrome.

Hypersensitivity or **allergic reactions** reflect drug-related immunogenicity. Therapeutic

peptides or proteins with molecular weights >600 daltons are recognized by the immune system as foreign substances and can directly trigger allergic reactions. Drugs with molecular weights <600 daltons are too small to act as direct immunogens; however, these drugs may act as **haptens**. Haptens bind covalently to large endogenous protein molecules and the hapten-protein complex triggers the allergic response.

The Gell-Coombs classification system proposes four mechanisms of hypersensitivity or allergic reactions: type I or immediate hypersensitivity reactions (anaphylaxis), type II or antibody-dependent cytotoxic reactions, type III or immune complex-mediated reactions (serum sickness), and type IV or delayed T cell-mediated reactions.^{1,3} An allergic response is predicated on sensitization, i.e., prior exposure to a drug. At highest risk are adults, women, patients with HIV infection, and those with history of allergy to related drugs.

Type I or immediate hypersensitivity reactions (anaphylaxis) are predicated on exposure to an allergen and antigen-specific antibody production dominated by immunoglobulin E (IgE) isotype.^{1,3} Upon re-exposure IgE antibodies bind to mast cells in mucosal and epithelial tissues (Figure 1). The simultaneous binding of an antigen to adjacent IgE molecules fixed to Fc receptors

triggers degranulation of mast cells resulting in the production and release of histamine, leukotrienes, prostaglandins, and cytokines.

Type II or antibody-dependent cytotoxic reactions are predicated on exposure to an allergen and antigen-specific antibody production dominated by immunoglobulin G (IgG) or M (IgM) isotypes.^{1,3} Upon re-exposure the antigen binds to the surface of target cells (usually RBCs), the antigen-antibody complexes attract cytotoxic T cells, which release chemical mediators that cause target-cell lysis (Figure 2). Alternatively, antigen-antibody complexes attached to target-cells may activate complement-mediated target-cell lysis.

Type III or immune complex-mediated reactions (serum sickness) are predicated on exposure to an allergen and antigen-specific antibody production dominated by immunoglobulin G (IgG) or M (IgM) isotypes.^{1,3} Upon re-exposure soluble drug molecules form large insoluble antigen-antibody complexes that are deposited in target tissues (e.g., kidneys, joints and lungs) and initiate complement activation, neutrophil and platelet aggregation, and an intense inflammatory response (Figure 3).

Type IV or delayed T cell-mediated hypersensitivity reactions are predicated on exposure to haptens, which bind to




Figure 1. Type I or Immediate Hypersensitivity Reaction.




Figure 2. Type II or Antibody-dependent Hypersensitivity Reaction.




Figure 3. Type III or Immune Complex-mediated Reaction.

endogenous macromolecules and form hapten-protein complexes.^{1,3} Langerhans cells phagocytize and process hapten-protein complexes, load them into major histocompatibility complexes, migrate to regional lymph nodes and present them to naïve T-lymphocyte. Upon re-exposure sensitized T cells in target tissues activate macrophages, which mediate direct cellular damage (Figure 4).

Mechanisms of Idiosyncratic ADRs

Idiosyncratic ADRs are unpredictable and affect a small number of patients. Factors influencing drug response phenotype include age, gender, underlying disease, and genetic and epigenetic mechanisms.^{1,4,5} Genetic polymorphism and epigenetic factors (i.e., heritable changes in gene function and expression not related to DNA sequencing) influence the outcome of




Figure 4. Delayed T Cell-mediated Hypersensitivity Reaction.

pharmacotherapy and have been implicated in both pharmacokinetic and pharmacodynamic variations.

Inherited variations in enzymes that catalyze drug metabolism are the most common causes of variation in response to medications. The effects of genetic polymorphism on drug metabolism are the most prominent with five isoforms of the cytochrome P450 enzymes, i.e., CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Isoenzyme-induced variations in drug metabolism may lead to significant differences in the efficacy and toxicity of drugs.

Mechanisms of Oncogenic ADRs

Oncogenesis is a complex process involving genetic and epigenetic changes that result in an imbalance between cell division and apoptosis (programmed cell death).¹ Among the known factors implicated as potential “initiators” and/or “promoters” of cancer are tobacco, alcohol, solar radiation, ionizing radiation, occupational carcinogens, environmental pollutants, infectious agents, nutrients, and rarely, medications.

Primary oncogenic effects can be produced by drugs (initiators) that damage DNA or by drugs (promoters) that facilitate proliferation of cells carrying precancerous mutations.¹ Drugs that act

as initiators are drugs that have been converted into reactive metabolites by polymorphic oxidation reactions. These reactive metabolites bind covalently to DNA in proto-oncogenes or tumor-suppressor genes, modify DNA, and lead to mutations.

Proto-oncogenes are normal genes that promote cell division. **Oncogenes** are proto-oncogenes, which through amplification or mutation became permanently activated allowing abnormal cells to survive and proliferate. **Tumor suppressor genes** are normal genes that slow down cell division, repair damaged DNA, or initiate apoptosis. Through mutations, tumor suppressor genes are inactivated leading to uncontrolled cell growth.

For example, activated oncogenes and inactivated tumor suppressor genes may alter the expression of cell-cycle regulatory proteins (e.g., cyclin-dependent kinases) that govern the initiation, progression, and completion of cell-cycle events, causing overexpression of cyclins and loss of expression of cyclin-dependent kinase inhibitors. Deregulated cyclin-dependent kinase activity provides malignant cells with a selective growth advantage.

Secondary oncogenic effects are related to therapeutic immunosuppression. Reactivated **latent oncogenic viruses** can induce mutations,

gene amplifications, or chromosome rearrangements in host DNA.⁶ There are seven known human oncogenic viruses (Table 1). Human oncogenic DNA viruses include the Epstein-Barr virus, human papilloma viruses, hepatitis B virus, and herpes simplex virus-8, and Merkel cell polyomavirus. Human oncogenic RNA viruses include human T-lymphotropic virus type 1 and hepatitis C virus.

Mechanisms of Teratogenic ADRs

Teratogenesis is the process that results in structural and/or functional defects in a fetus.^{1,7}

A **teratogen** is any agent that can induce teratogenesis. While drugs are most frequently implicated, other potential teratogens include: radiation exposure, Zika virus, and lead exposure. Overall, an estimated 5% of birth defects are believed to be caused by a known

teratogen.⁷ Drug teratogenicity depends on the ability of the teratogen to diffuse from the maternal circulation across the placenta. The extent of diffusion depends on the chemical nature of the agent (molecular weight, protein binding capacity, lipid solubility, and pKa) and maternal pharmacokinetic factors.

Teratogens present the greatest risk to the embryo during periods of intense mitotic activity. Exposure to a teratogen from the time of conception to day seventeen results in spontaneous abortion. Exposure to a teratogen during organogenesis, i.e., from day 18 to day 55 results in developmental abnormalities (Figure 5). The period from day 55 through the 3rd trimester is a period of fetal growth, during which exposure to a teratogen affects organ function.

| Table 1. Human Oncogenic Viruses ⁽⁶⁾ | | |
|-------------------------------------------------|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|
| Virus Type | Virus | Associated Malignancies |
| DNA | Epstein-Barr virus | Hodgkin lymphoma (40%) Burkitt lymphoma (95%) Gastric carcinoma (10%) Nasopharyngeal carcinoma (most) Other lymphomas |
| | Human papillomavirus | Cervical carcinoma (>95%) Oropharyngeal carcinoma (70%) Anogenital carcinomas |
| | Hepatitis B virus | Hepatocellular carcinoma (>50%) |
| | Herpes simplex virus-8 | Kaposi (99%) |
| | Merkel cell polyomavirus | Merkle cell carcinoma (80%) |
| RNA | Human T-lymphotropic virus 1 | Adult T cell lymphoma (99%) |
| | Hepatitis C virus | Hepatocellular carcinoma (25%) Non-Hodgkin B cell lymphomas |




Figure 5. Periods of Increased Organ-specific Sensitivity of Fetal Tissues to Teratogens.

Clinical Manifestations of ADRs

The Council of International Organizations of Medical Sciences (CIOMS) published guidelines on diagnostic criteria and basic requirements for standardized reporting of ADRs.⁸ This is especially relevant since most reporting is based on single cases. The CIOMS codified ADRs under 21 major headings and defined 179 conditions considered reportable. However, there is no specific major heading for ADRs affecting oral tissues.

ARDs related to immune-mediated and idiosyncratic mechanisms among the 30 most common ADRs associated with therapeutic doses of drugs in the top 200 dispensed by U.S. community pharmacies include rash, pruritus, allergic reactions, urticaria, arthralgia, and anaphylaxis.⁹ In addition, less common ADRs affecting oral tissues, rare oncogenic and teratogenic ADRs, and some secondary ADRs are discussed.

DailyMed is the official website for FDA-approved label (package insert) information.¹⁰ It provides a centralized, standard, comprehensive, up-to-date, look-up-and-download resource for package inserts submitted to the FDA by pharmaceutical companies. The website is user-

friendly, it includes strengthened warnings undergoing FDA review, and it is a reliable resource for information on known potential ADRs related to specific drugs.

ADRs Affecting Skin (Mucosa) and Appendages

Rash was the 6th most common ADR associated with the top 200 drugs dispensed by U.S. community pharmacies in 2008.⁹ However, rash is a general term and CIOMS discourages its use as it encompasses virtually all skin eruptions.⁸ **Pruritus** or itching was the 10th most frequently cited ADR and may be a symptom of primary skin lesions or less frequently that of a systemic disease.¹¹ However, itching may also be the result of drug-induced histamine release by mast cells unrelated to the immune system or it may reflect a bona fide drug-related allergic reaction.¹¹

Opioid analgesics, especially when used for epidural and intrathecal anesthesia, frequently induce pruritus and also have the ability to induce peripheral histamine release.¹² Vancomycin and ciprofloxacin can cause **red man syndrome** which is characterized by itching followed by the emergence of a “rash” or hives, i.e., urticaria.¹ Other drugs that can cause itching and urticaria include NSAIDs, penicillin, and some

antifungal agents. These reactions are unrelated to IgE-induced mast cell degranulation and have been called **anaphylactoid** or **pseudoallergic reactions**.⁸

Urticaria the 16th most frequently reported ADR reported in 2008, is a well-circumscribed erythematous, pruritic plaque on skin associated with the release of histamine and other vasoactive substances from mast cells and basophils resulting in intradermal edema caused by vasodilation.^{8,9,12} As noted, this may be due to direct non-allergenic activation of mast cells by drugs or drug-induced cyclooxygenase inhibition-related mast cell degranulation. **Chronic urticaria** (> 6 weeks) is usually idiopathic or it may be associated with auto-antibodies to IgE receptors causing mast cell degranulation.¹²

Acute urticaria (< 6 weeks) most often reflects a hypersensitivity or allergic reaction in which allergen-bound IgE initiates mast cell and basophil degranulation (Figures 6 and 7).¹² It may be noted in susceptible patients within minutes or hours following exposure usually by

contact or inhalation to an allergen such as latex proteins; and it may be precipitated by exposure to many prescription and over-the-counter medications. A common feature of pruritus and urticaria is subcutaneous and submucosal angioedema of target tissues.^{8,12}

Angioedema is a swelling (usually localized) of the subcutaneous tissues usually mediated by either mast cell-derived mediators (e.g., histamine, leukotrienes, prostaglandins) or bradykinin and complement-derived mediators.¹³ A few cases are hereditary. Angioedema may be acute and chronic. **Acute angioedema** (< 6 weeks) is mast-cell mediated in >90% of cases. While it may be localized, swelling of the extremities, face, lips (Figure 8), tongue, oropharynx (Figure 9), and larynx along with stridor, wheezing, and hypotension are harbingers of anaphylaxis.^{8,13} Another important variant of acute angioedema is caused by increased bradykinin activity associated angiotensin-converting enzyme (ACE) inhibitors. The face and upper airways are most affected, but urticaria does not occur. This variant is estimated to account for up to 30% of cases of



Figure 6. Acute urticaria following the oral administration of penicillin.



Figure 7.



Figure 8. Acute angioedema of the lips and oropharynx following the oral administration of penicillin.



Figure 9.

acute angioedema presenting to emergency departments and may occur soon or years after ACE inhibitor therapy initiation.

Chronic angioedema (> 6 weeks) is rarely IgE-mediated; it is usually idiopathic and may be caused by the chronic ingestion of certain drugs (e.g., penicillin), preservatives, milk, and food additives; and a few cases are hereditary.¹³

A specific mucocutaneous ADR of interest to oral healthcare providers is **erythema multiforme** (EM).¹⁴⁻¹⁷ EM is an acute T cell-mediated cytolytic reaction to immune-complex mechanisms involving antigen-antibody reactions that target small blood vessels in the skin or mucosa. About 90% of cases are precipitated by infection, with herpes simplex most frequently implicated. Other precipitating or triggering factors include medications (e.g., sulfonamides, NSAIDs, penicillins, anticonvulsants), foods, food additives, and inflammatory bowel disease. Cutaneous lesions begin as erythematous papules that progress to form the more characteristic iris or target lesions (Figure 10).¹⁴⁻¹⁷ Hemorrhagic crusting of the lips (Figure 11)

and vesiculoerosive lesions on unattached oral mucosal tissues are considered pathognomonic.

Severity of EM varies from mild (EM minor) to moderate (EM major) and to potentially fatal **Stevens-Johnson syndrome** (SJS) or **toxic epidermal necrolysis** (TEN).^{8,14-17} The majority of SJS and TEN cases are precipitated by drugs. Oral features of SJS and TEN are similar to those associated with EM. The major difference between SJS and TEN is the distribution of dermal lesions. SJS affects <10% of the body surface while TEN affects >30%. Skin involvement of 10% to 30% of the body surface is considered SJS-TEN overlap.

Extrinsic antigenic sources such as drugs have been identified as agents responsible for oral lichen planus (OLP)-like lesions. Drugs such as NSAIDs and ACE inhibitors can act as haptens and alter the antigenicity of epithelial self-antigens. OLP that can be traced to an extrinsic cause is more properly termed a **lichenoid reaction**.^{8,15-17} Oral lichenoid lesions most often affect the buccal mucosa (Figures 12 and 13), gingivae, the lateral border of the tongue and may be “reticular”, atrophic, or erosive.



Figure 10. Characteristic iris or target lesions of the skin and serohemorrhagic crusting of the lips associated with erythema multiforme following the administration of ibuprofen.



Figure 11. Serohemorrhagic crusting of the lips associated with erythema multiforme following the administration of ibuprofen.



Figure 12. Lichenoid stomatitis in a patient with rheumatoid arthritis taking ibuprofen.




Figure 13. Lichenoid stomatitis in a patient with rheumatoid arthritis taking ibuprofen.

Arthralgia was the 24th most commonly reported ADR associated with the top 200 drugs in 2008.⁹ Arthralgia may be described as sharp or dull, stabbing, burning or throbbing, and may range in intensity from mild to severe. A large and heterogeneous group of drugs have been implicated to include antimicrobials, anti-mycobacterials, antifungals, antidiabetics, chemotherapeutics, retinoids, cytokines, and psychotropics. ACE-inhibitors, bisphosphonates, fluoroquinolones, corticosteroids, and vaccines. Not surprisingly, no predominant pathogenetic mechanism has been identified.¹⁸ The most common cause of arthralgia is arthritis; other causes include injury and infection.

Hypersensitivity-related ADRs

Type I hypersensitivity reactions or anaphylaxis are acute, IgE-mediated systemic reactions that occur within minutes to hours after parenteral or enteral administration of a drug in a previously sensitized patient.^{1,3,16} The shorter the reaction time, the more severe the reaction is. Following enteral administration of an allergen the reaction may be delayed or less severe. Anaphylaxis may simultaneously involve multiple organ systems reflected in one or more of the following signs and symptoms:^{8,16}

- Skin: pruritus, erythema, urticaria, angioedema
- Respiratory system: laryngeal edema and/or spasm, bronchospasm
- Gastrointestinal system: abdominal cramps, vomiting, diarrhea
- Central nervous system: anxiety, agitation, loss of consciousness

- Cardiovascular system: tachycardia or bradycardia, hypotension, shock

Type II antibody-dependent hypersensitivity or cytotoxic reactions occur when a drug binds to target cells, usually RBCs, and is recognized by IgG or IgM antibodies.^{1,3,16} The time required for cytotoxic T cell-mediated target cell lysis or for target cell lysis mediated by the complement system in response to a specific antigen is variable. Clinical manifestations include hemolytic anemia, neutropenia, and thrombocytopenia. Type II reactions are rare, but may be precipitated by several drugs such as penicillin.

Type III or immune complex-mediated hypersensitivity reactions (serum sickness) may occur within 6-10 days after initial exposure to a foreign protein such as monoclonal or polyclonal antibodies prepared from horse, rabbit, or mouse serum.^{1,3,16} Upon re-exposure, however, serum sickness develops sooner. Serum sickness-like reactions have been noted in association with non-protein drugs such as penicillins, cephalosporins, sulfonamides, bupropion, fluoxetine, and thiouracil, metronidazole, tetracyclines (Figure 14 and 15), and NSAIDs.

Common symptoms of serum sickness include fever, cutaneous eruptions (usually urticaria), arthralgia, headaches, myalgia, dyspnea and wheezing, and lymphadenopathy.¹⁹ Angioedema of the face and neck may occur. Serum sickness is typically self-limiting and resolves within 1-2 weeks after removal of the offending agent.^{15,19}



Figure 14. Type III or immune complex-mediated hypersensitivity reaction with vasculitis in response to tetracycline therapy.




Figure 15.

Type IV hypersensitivity or delayed T cell-mediated reactions are mediated by immunologically committed T lymphocytes. In susceptible patients, cytokines and other mediators of inflammation are released within 2 to 7 days of re-exposure to an allergen.^{1,3,16} Clinical manifestations include allergic contact dermatitis/mucositis (Figures 16 and 17) or a drug-induced maculopapular rash. With repeated antigenic challenge, the response becomes more profound and includes fever, malaise, and angioedema in target tissues.

Idiosyncratic ADRs

As noted earlier, idiosyncrasy is an unpredictable reaction of any intensity observed in a small number of the individuals.¹⁴ When a drug produces its usual effect on a person at an unexpectedly high dose, the patient is said to be **hyporeactive**. When a drug produces its effect at an unexpectedly low dosage, the patient is said to be **hyperreactive**. Some of this diversity in response rates can be attributed to differences in the rate of drug metabolism by the various cytochrome P450 enzymes.

For example, codeine, a pro-drug, is metabolized by demethylation into morphine, its active metabolite, by the cytochrome P450 isoenzyme CYP2D6.²⁰ Isoenzyme CYP2D6 is subject to genetic polymorphism. Up to 10% of patients are poor metabolizers of codeine and do not experience analgesia in response to treatment with codeine. Another 10% of the patients are rapid metabolizers of codeine, i.e., they rapidly convert codeine to morphine

and may experience severe toxicity (including death), even with therapeutic doses.

Primary Oncogenesis-related ADRs

In general, drugs that cause direct damage to DNA and/or that interfere with DNA repair are avoided in clinical practice. However, DNA damage and/or interference with DNA repair is the specific intent of cytotoxic alkylating agents used to treat neoplasia and such drugs can cause acute **myelocytic leukemia**.¹ Tamoxifen, an estrogen receptor antagonist used to treat estrogen-sensitive breast cancer, acting as a partial agonist at estrogen receptors in the uterus can cause **endometrial carcinoma**.¹

Teratogenesis-related ADRs

Only a small number of drugs in clinical use have been positively implicated in teratogenesis. Of note for oral healthcare providers are the tetracyclines. They induce **enamel hypoplasia, discoloration of teeth, and diminished growth of long bones**.^{21,22} Furthermore, they produce higher rates of **neuronal-tube defect, cleft palate**, and multiple congenital abnormalities such as **neuronal-tube defect with cardiovascular malformation**.²³

Recent evidence suggests that acetaminophen (APAP) may interfere with neurodevelopment and children prenatally exposed to acetaminophen were more likely to develop autism spectrum and attention-deficit and hyperactivity symptoms.^{24,25} While the risk appears to be dose related, practitioners should only prescribe APAP to the pregnant patient only when necessary.²⁴



Figure 16. Type IV or Delayed Hypersensitivity Reaction in Response to a Cinnamon-flavored Sugar-free Gum.



Figure 17. Type IV or Delayed Hypersensitivity Reaction in Response to an OTC Lip Balm Containing Benzocaine.

Secondary ADRs Related to Therapeutic Immunosuppression

Bacterial infections often contribute to morbidity and mortality associated with therapeutic immunosuppression.^{15,17} A wide range of bacteria, including odontopathic, peri-odontopathic, and transient pathogens of the oral flora may manifest as ulcerative lesions. The normal signs of infection such as inflammation are not always obvious, with pain, fever, and the presence of a lesion observed most consistently (Figure 18).



Figure 18. Coagulase-negative staphylococcal infection in a patient with leukemia undergoing chemotherapy.

Therapeutic immunosuppression is often complicated by **fungal infections** such as those associated with the *Candida* sp.^{15,17} Oral candidiasis may appear as white, raised, or cottage cheese-like growths that can be scraped off, leaving a red and sometimes hemorrhagic base. Via deglutition, droplet aspiration, or the hematological route oral candidiasis may spread to the esophagus or lungs; and, eventually, may affect all organ systems (Figures 19 and 20).



Figure 19. Severe oral, dermal, and nail infection with candidal organisms in a patient undergoing immunosuppressive therapy prior to bone marrow transplantation.

Viral infections in patients undergoing therapeutic immunosuppression include recurrent herpes simplex virus (HSV) infections affecting the lips and intraoral tissues (Figure 21).¹⁷ The ulcerations are quite painful. The optimal period of observation for the detection of recurrent HSV infections is during the 7- to 14-day period following immunosuppression. Primary HSV infections account for less than 2% of infections in this patient population.

Herpes zoster (HZ) is a common clinical manifestation of immunosuppression-induced reactivation of the latent varicella zoster virus.¹⁷ It is a localized, painful vesicular rash with an erythematous base restricted to skin and mucosal tissues and follows the distribution of a branch of the trigeminal nerve (Figures 22 and 23). Lesions are usually unilateral, deeper seated and more closely aggregated than those associated with chickenpox.

Epstein-Barr virus (EBV) infection has been associated with a wide range of syndromes in solid organ transplant recipients.²⁷ In the oral cavity, the EBV has been causally related to hairy leukoplakia, characteristically found on the lateral borders of the tongue in patients with therapeutic immunosuppression (Figure 24). As noted earlier, the EBV is an oncogenic virus, which when reactivated may also cause secondary malignancies.

Secondary malignancies related to therapeutic immunosuppression in susceptible individuals include de novo squamous cell carcinoma of the skin and lip (Figure 25).²⁸ Secondary malignancies related to immunosuppression-induced reactivation of oncogenic viruses include Kaposi sarcoma



Figure 20.



Figure 21. Atypical herpes labialis secondary to the reactivation of the latent HSV in a patient with leukemia undergoing chemotherapy.



Figure 22 and 23. Herpes zoster infection involving the maxillary and ophthalmic divisions of the trigeminal nerve secondary to the reactivation of the latent VZV in a patient with leukemia undergoing chemotherapy.

(Figure 26), lymphoproliferative diseases (Figure 27), Hodgkin's and non-Hodgkin's lymphomas, and spindle-cell sarcoma (Figure 28).²⁸

Withdrawal Syndrome

Withdrawal syndrome is a substance-specific ADR associated with cessation or rapid reduction in the amount of a substance that an individual (usually a substance-dependent person) has been taking for a prolonged period of time and/or in high doses.⁸ It results in clinically significant physiological or psychological distress or impairment in social, occupational or other important areas of functioning. It is most commonly associated with alcohol, tobacco, cocaine, amphetamines, and heroin addiction; and following the long-term use of therapeutic agents such as opioids and benzodiazepines. The signs and symptoms of withdrawal are specific to the specific agent withheld and commonly observed signs and symptoms are summarized in Table 2²⁹, but often include.

Preventing ADRs

Preventing ADRs is a critical part of clinical practice. Oral healthcare providers must have an awareness of and access to information related to ADRs. To minimize such events, they must develop a rational approach to the use of pharmacotherapeutic agents in the management of oral/odontogenic problems; especially, since in the treatment of most such conditions non-pharmacological intervention



Figure 24. Hairy leukoplakia secondary to the reactivation of the latent EBV in a patient on therapeutic immunosuppression following renal transplantation.



Figure 25. Squamous cell carcinoma of the lip in a patient 2 years after renal transplantation.



Figure 27. Epstein-Barr virus-related lymphoproliferative disease in a patient 3 years after renal transplantation.



Figure 26. Human herpesvirus-8-related Kaposi sarcoma of the palate in a patient 4 years after renal transplantation.



Figure 28. Epstein-Barr virus-related spindle cell sarcoma in a patient 4 years after renal transplantation.

such as primary dental care is a more effective and safer alternative than pharmacotherapy.³⁰

Inappropriate overprescribing is a major concern in healthcare and practitioners must caution against prescribing out of convenience or to meet patient demand.^{1,31-34} Overprescribing not only contributes to ADR risk, but also antimicrobial resistance and opioid habituation.

The benefits should always outweigh the risks when a drug is prescribed. If clinicians were to observe this basic principle routinely, then the number of unnecessary or inappropriate prescriptions would be reduced. Drug therapy should be individualized by taking into consideration both drug- and patient-related variables.³⁵⁻³⁷ Patient-related factors that contribute to ADR risk include progressing age, multiple co-morbidities, living alone, and poor coping skills of ambulatory patients.

When a medication is prescribed, the patient and/or guardian/caretaker must have a clear understanding of its purpose and dosing. Simple and clear oral instructions on how and when to

take a drug should be given and reinforced by clear labeling and written instructions. Special labels are available for blind or poorly sighted patients.

Follow-up should be accomplished to assess the patient's compliance and response to drug therapy. The patient should be encouraged to report any potential ADR so that appropriate action can be taken, e.g., dosage adjustments or discontinuance of medication. Complex regimens and frequent dosing lend themselves to noncompliance. A byproduct of poor compliance is hoarding of drugs, which can further contribute to noncompliance and ADRs as patients may confuse new bottles with old ones or use hoarded drugs for the wrong purpose.

Diagnosing ADRs

The diagnosis of ADRs is highly subjective and imprecise. Complaints such as fatigue, inability to concentrate, and excessive sleepiness have been reported by healthy individuals not taking medications. It is also well known that patients receiving a placebo report ADRs. However, drugs as disease and symptom producing agents

| Table 2. Common Signs & Symptoms of Drug Withdrawal ⁽²⁹⁾ | | |
|---------------------------------------------------------------------|----------------------|----------------------------|
| Trembling and tremors | Muscle pain or aches | Hunger or loss of appetite |
| Fatigue | Sweating | Irritability and agitation |
| Depression | Anxiety | Nausea |
| Vomiting | Confusion | Insomnia |
| Paranoia | Seizures | Dilated pupils |

should always be considered in the formulation of a differential diagnosis and the following step-wise process can be helpful in assessing possible drug-related adverse reactions:

- Step 1 – Identify the drug(s) taken by the patient.
- Step 2 – Verify that the onset of signs and symptoms was after the initiation of pharmacological intervention.
- Step 3 – Determine the time-interval between the initiation of drug therapy and the onset of signs and symptoms.
- Step 4 – Stop drug therapy and monitor signs and symptoms.
- Step 5 – In rare instances it may be appropriate to restart drug therapy and monitor for recurrence of signs and symptoms.

Reporting ADRs

The FDA has the responsibility for ensuring the safety of all marketed drugs; and, consequently, for maintaining a post-marketing surveillance program to identify ADRs. The success of this program depends on active participation by all clinicians. The FDA launched **MedWatch**, an initiative designed to educate health care professional about the critical importance of being aware of, monitoring for, and reporting ADRs.³⁸

It is of import to note that the reporting clinician is not responsible for proving causality; a suspected association constitutes sufficient reason to report. The FDA holds the identity of the patient in strict confidence. However, unless otherwise indicated on the reporting form, the reporting clinician’s identity may be shared with

the manufacturer of the drug. Reports may be sent directly to the FDA by several different mechanisms:

- [View Form FDA 3500 Instructions](#)
 - [Complete voluntary Form FDA 3500 online](#)
 - Call 1-800-FDA-1088 to report by telephone
 - [Download form](#) or call 1-800-332-1088 to request a reporting form
 - Complete and return the form to the address on the pre-addressed form, OR
 - Submit the form by fax to 1-800-FDA-0178

Based on these reports, the FDA may send out “Dear Health Professional” letters; require warning labels and/or changes to the packaging information (package insert); request further epidemiological investigations and/or manufacturer-sponsored post-marketing studies; and conduct inspections of manufacturers’ facilities and/or records. Ultimately, the FDA may require withdrawal of the drug from the market.

Summary

In considering ADRs in the differential diagnosis of a patient’s problem, the practitioner must acknowledge that there are no “absolutely safe” medications and be familiar with relevant literature about ADRs. It is equally important to recognize that some ADRs occur sporadically and detection based on clinical experience or reports in the literature are lacking. Improved reporting of ADRs can save lives, reduce morbidity, and decrease the cost of healthcare.

Course Test Preview

To receive Continuing Education credit for this course, you must complete the online test. Please go to: www.dentalcare.com/en-us/ce-courses/ce537/start-test

1. Major categories of ADRs related to the immune system include all of the following, EXCEPT for one. Which one is the exception?

- A. immunotoxicity
- B. autoimmune reactions
- C. hypersensitivity or allergic reactions
- D. Habituation

2. All of the following statements related to autoimmune reactions are correct, EXCEPT for one. Which one is the exception? An autoimmune reaction may _____.

- A. be the specific intent of therapy, e.g., when monoclonal antibodies target specific B cells
- B. elicit an antibody response to Rh factors on red blood cells (RBCs) causing hemolytic anemia
- C. induce an antibody response to myeloperoxidase or DNA causing a lupus-like syndrome
- D. directly cause mast cell degranulation resulting in urticarial lesions

3. All of the following statements related to hypersensitivity or allergic reactions are correct, EXCEPT for one. Which one is the exception?

- A. Therapeutic peptides or proteins with molecular weights >600 daltons are recognized by the immune system as foreign substances and can directly trigger allergic reactions.
- B. Drugs with molecular weights <600 daltons are too small to act as direct immunogens; however, these drugs may act as haptens.
- C. The Gell-Coombs classification system consists of five mechanisms of hypersensitivity or allergic reactions.
- D. An allergic response is predicated on sensitization, i.e., prior exposure to a drug.

4. All of the following statements related to Type I or immediate hypersensitivity reactions (anaphylaxis) are incorrect, EXCEPT for one. Which one is the exception?

- A. Type I reactions are predicated on exposure to an allergen and antigen-specific antibody production dominated by immunoglobulin E (IgE) isotype.
- B. Type I reactions are predicated on exposure to an allergen and antigen-specific antibody production dominated by immunoglobulin G (IgG) or M (IgM) isotypes.
- C. Type I reactions are predicated on exposure to haptens, which bind to endogenous macromolecules and form hapten-protein complexes.
- D. In Type I reactions Langerhans cells phagocytize and process hapten-protein complexes, load them into major histocompatibility complexes, migrate to regional lymph nodes and present them to naïve T-lymphocyte.

5. All of the following statements related to Type IV or delayed T-cell mediated hypersensitivity reactions are incorrect, EXCEPT for one. Which one is the exception? Upon re-exposure to a specific antigen, _____.

- A. IgE antibodies bind to mast cells in mucosal and epithelial tissues and trigger degranulation of mast cells resulting in the production and release of histamine, leukotrienes, prostaglandins, and cytokines
- B. the antigen binds to the surface of target cells (usually RBCs), the antigen-antibody complexes attract cytotoxic T cells, which release chemical mediators that cause target-cell lysis
- C. soluble drug molecules form large insoluble antigen-antibody complexes that are deposited in target tissues (e.g., kidneys, joints and lungs) and initiate complement activation, neutrophil and platelet aggregation, and an intense inflammatory response
- D. sensitized T cells in target tissues activate macrophages, which mediate direct cellular damage

- 6. All of the following statements related to idiosyncratic ADRs are correct, EXCEPT for one. Which one is the exception?**
- A. Idiosyncratic ADRs are observed in a small number of patients.
 - B. Idiosyncratic ADRs are predictable.
 - C. Factors influencing drug response phenotype include age, gender, underlying disease, and genetic and epigenetic mechanisms.
 - D. Genetic polymorphism and epigenetic factors have been implicated in both pharmacokinetic and pharmacodynamic variations.
- 7. All of the following statements related to oncogenic mechanisms of ADRs are correct, EXCEPT for one. Which one is the exception?**
- A. Primary oncogenic effects can be produced by drugs that damage DNA or by drugs that facilitate proliferation of cells carrying precancerous mutations.
 - B. Oncogenes are proto-oncogenes, which through amplification or mutation became permanently activated allowing abnormal cells to proliferate.
 - C. Inactivated tumor suppressor genes slow down cell division, promote the repair of damaged DNA, and initiate apoptosis.
 - D. Secondary oncogenic effects are related to therapeutic immunosuppression-induced reactivation of latent oncogenic viruses.
- 8. All of the following statements related to teratogenesis are correct, EXCEPT for one. Which one is the exception?**
- A. Teratogenesis is the process that results in structural and/or functional defects in a fetus.
 - B. Exposure to a teratogen during organogenesis, i.e., from day 18 to day 55 results in developmental abnormalities.
 - C. The period from day 55 through the 3rd trimester is a period of fetal growth, exposure to a teratogen affects organ function.
 - D. Teratogens present the greatest risk to the embryo during periods of subdued mitotic activity.
- 9. All of the following statements related to rash or pruritus are correct, EXCEPT for one. Which one is the exception?**
- A. Rash is a specific term and its use is encouraged in describing an ADR characterized by skin eruption.
 - B. Pruritus may be a symptom of primary skin lesions or less frequently that of a systemic disease.
 - C. Pruritus may be the result of drug-induced histamine release by mast cells unrelated to the immune system.
 - D. Pruritus may reflect a bona fide drug-related allergic reaction.
- 10. All of the following ADRs are likely to be unrelated to IgE-induced mast cell degranulation and be described as an anaphylactoid or pseudoallergic reaction, EXCEPT for one. Which one is the exception?**
- A. Opioid analgesic-induced central pruritic action and peripheral histamine release.
 - B. Vancomycin and ciprofloxacin-induced red man syndrome characterized by itching followed by the emergence of a "rash" or hives, i.e., urticaria.
 - C. Some cases of NSAID-, penicillin-, and antifungal agent-induced itching and urticaria.
 - D. Type III immune reactions, such as serum sickness.

11. All of the following statements related to urticaria are correct, EXCEPT for one. Which one is the exception?

- A. Urticaria is a well-circumscribed erythematous, pruritic plaque on skin associated with the release of histamine and other vasoactive substances from mast cells and basophils resulting in intradermal edema caused by vasodilation.
- B. A rare feature of urticaria is subcutaneous and submucosal angioedema of target tissues.
- C. Chronic urticaria is usually idiopathic or it may be associated with auto-antibodies to IgE receptors causing mast cell degranulation.
- D. Acute urticaria most often reflects a hypersensitivity or allergic reaction in which allergen-bound IgE initiates mast cell and basophil degranulation.

12. All of the following statements related to angioedema are correct, EXCEPT for one. Which one is the exception?

- A. Acute angioedema (< 6 weeks) is bradykinin-mediated in >90% of cases.
- B. Chronic angioedema is rarely IgE-mediated; it is usually idiopathic and may be caused by the chronic ingestion of certain drugs (e.g., penicillin), preservatives, milk, and food additives; and a few cases are hereditary.
- C. While it may be localized, swelling of the extremities, face, lips, tongue, oropharynx, and larynx along with stridor, wheezing, and hypotension are harbingers of anaphylaxis.
- D. Bradykinin mediated angioedema may occur soon or years after ACE inhibitor therapy initiation.

13. All of the following statements related to erythema multiforme (EM) are correct, EXCEPT for one. Which one is the exception?

- A. EM is an acute T cell-mediated cytolytic reaction.
- B. The majority of EM cases are drug-induced related to NSAIDs, penicillins, anticonvulsants, and sulfonamides.
- C. Cutaneous lesions begin as erythematous papules that progress to form the more characteristic iris or target lesions.
- D. Hemorrhagic crusting of the lips and vesiculoerosive lesions on unattached oral mucosal tissues are considered pathognomonic.

14. All of the following statements related to EM, Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) are correct, EXCEPT for one. Which one is the exception?

- A. Severity of EM varies from mild (EM minor) to moderate (EM major) to potentially fatal SJS or TEN.
- B. The majority of SJS and TEN cases are associated with the herpes simplex virus.
- C. Oral features of SJS and TEN are similar to those associated with EM.
- D. The major difference between SJS and TEN is the distribution of dermal lesions: SJS affects <10% of the body surface while TEN affects >30%.

15. All of the following statements related to lichenoid reactions are correct, EXCEPT for one. Which one is the exception?

- A. Drugs such as NSAID's and ACE inhibitors can act as haptens and alter the antigenicity of epithelial self-antigens.
- B. Oral lichen planus that can be traced to an extrinsic cause is more properly termed a lichenoid reaction.
- C. Oral lichenoid lesions may be "reticular", atrophic, or erosive.
- D. Oral lichenoid most often affect the palate.

- 16. All of the following statements related to arthralgia are correct, EXCEPT for one. Which one is the exception?**
- A. Drugs associated with arthralgia include antimicrobials, anti-mycobacterials, antifungals, antidiabetic, chemotherapeutics, retinoids, cytokines, and psychotropics.
 - B. The most common cause of arthralgia is arthritis; other causes include injury and infection.
 - C. A single unifying mechanism of action has been determined to explain ADR-related arthralgia.
 - D. Arthralgia is the 24th most commonly reported ADR associated with the top 200 drugs.
- 17. All of the following statements related to Type I hypersensitivity reactions are correct, EXCEPT for one. Which one is the exception?**
- A. Anaphylaxis occurs within minutes to hours after parenteral or enteral administration of a drug in a previously sensitized patient.
 - B. The longer the reaction time to an antigen, the more severe the anaphylactic reaction is.
 - C. Skin-related signs and symptoms of anaphylaxis include erythema, urticaria, and angioedema.
 - D. Cardiopulmonary effects of anaphylaxis include bronchospasm, hypotension, and shock.
- 18. All of the following statements related to either a Type II or Type III hypersensitivity reaction are correct, EXCEPT for one. Which one is the exception?**
- A. The time required for cytotoxic T cell-mediated target cell lysis or for target cell lysis mediated by the complement system in response to a specific antigen is 1 to 3 weeks.
 - B. Clinical manifestations of Type II antibody-dependent cytotoxic reactions include hemolytic anemia, neutropenia, and thrombocytopenia.
 - C. Serum sickness-like reactions clinically similar to serum sickness have been noted in association with non-protein drugs such as penicillins, cephalosporins, sulfonamides, bupropion, fluoxetine, and thiouracil, metronidazole, tetracyclines, and NSAIDs.
 - D. Common symptoms of serum sickness include fever, cutaneous eruptions (usually urticaria), arthralgia, gastrointestinal complaints (nausea, vomiting, diarrhea, or abdominal pain), headaches, myalgia, dyspnea and wheezing, and lymphadenopathy.
- 19. All of the following statements related to Type IV hypersensitivity or delayed T cell-mediated reactions are correct, EXCEPT for one. Which is the exception?**
- A. Type IV hypersensitivity reactions are mediated by immunologically committed plasma cells.
 - B. In susceptible patients, cytokines and other mediators of inflammation are released within 2 to 7 days of re-exposure to an allergen.
 - C. Clinical manifestations include allergic contact dermatitis/mucositis or a drug-induced maculopapular rash.
 - D. With repeated antigenic challenge, the response becomes more profound and includes fever, malaise, and angioedema in target tissues.
- 20. All of the following statements related to idiosyncratic ADRs are correct, EXCEPT for one. Which one is the exception?**
- A. Idiosyncrasy is an unpredictable reaction of any intensity observed in a small number of the individuals.
 - B. When a drug produces its usual effect on a person at an unexpectedly high dose, the patient is said to be hyperreactive.
 - C. Because of genetic polymorphism, up to 10% of patients are poor metabolizers of codeine and do not experience analgesia in response to treatment with codeine.
 - D. Because of genetic polymorphism, up to 10% of patients are rapid metabolizers of codeine and may experience severe toxicity even with therapeutic doses.

21. All of the following statements related to primary oncogenesis-related ADRs is correct, EXCEPT for one. Which one is the exception?

- A. In general, drugs that cause direct damage to DNA and/or that interfere with DNA repair are avoided in clinical practice.
- B. DNA damage and/or interference with DNA repair is the specific intent of cytotoxic alkylating agents used to treat neoplasia and such drugs can cause acute myelocytic leukemia.
- C. Tamoxifen, an estrogen receptor antagonist used to treat estrogen-sensitive breast cancer, acting as a partial agonist at estrogen receptors in the uterus can cause endometrial carcinoma.
- D. Tamoxifen, an estrogen receptor antagonist used to treat estrogen-sensitive breast cancer, acting as a partial agonist at estrogen receptors in the uterus has been shown to decrease the risk of endometrial carcinoma.

22. All of the following statements related to teratogenesis-related ADRs are correct, EXCEPT for one. Which one is the exception?

- A. A large number of drugs in clinical use have been positively implicated in teratogenesis.
- B. Tetracyclines induce enamel hypoplasia, discoloration of teeth, and diminished growth of long bones.
- C. Tetracyclines produce higher rates of neuronal-tube defect, cleft palate, and multiple congenital abnormalities such as neuronal-tube defect with cardiovascular malformation.
- D. Recent evidence suggests that acetaminophen (APAP) may interfere with neurodevelopment and children prenatally exposed to acetaminophen were more likely acetaminophen (APAP) to develop autism spectrum and attention deficit and hyperactivity symptoms.

23. All of the following statements related to therapeutic immunosuppression-induced secondary ADRs are correct, EXCEPT for one. Which one is the exception?

- A. Bacterial infections often contribute to morbidity and mortality associated with therapeutic immunosuppression.
- B. Therapeutic immunosuppression is often complicated by fungal infections such as those associated with the *Candida* sp.
- C. Common viral infections in patients undergoing therapeutic immunosuppression include primary HSV infections.
- D. Herpes zoster (HZ) is a common clinical manifestation of immunosuppression-induced reactivation of the latent varicella zoster virus.

24. All of the following statements related to therapeutic immunosuppression-induced secondary malignancies are correct, EXCEPT for one. Which one is the exception?

- A. Secondary malignancies related to therapeutic immunosuppression in susceptible individuals include de novo squamous cell carcinoma of the skin.
- B. Secondary malignancies related to therapeutic immunosuppression in susceptible individuals include de novo squamous cell carcinoma of the lip.
- C. Secondary malignancies related to immunosuppression-induced reactivation of oncogenic viruses include hepatocellular carcinoma and cervical cancer.
- D. Secondary malignancies related to immunosuppression-induced reactivation of oncogenic viruses include Kaposi sarcoma, lymphoproliferative diseases, Hodgkin's and non-Hodgkin's lymphomas, and spindle-cell sarcoma.

- 25. All of the following statements related to withdrawal syndrome are correct, EXCEPT for one. Which one is the exception?**
- A. Withdrawal syndrome is a substance-specific ADR associated with cessation or rapid reduction in the amount of a substance that an individual has been taking for a prolonged period of time and/or in high doses.
 - B. Withdrawal syndrome results in clinically significant physiological or psychological distress or impairment in social, occupational or other important areas of functioning.
 - C. Withdrawal syndrome is most commonly associated with alcohol, tobacco, cocaine, amphetamines, and heroin addiction; and following the long-term use of therapeutic agents such as opioids and benzodiazepines.
 - D. The signs and symptoms of withdrawal syndrome are the same, regardless of the agent withdrawn.
- 26. All of the following statements related to preventing ADRs are correct, EXCEPT for one. Which one is the exception?**
- A. Preventing ADRs is a critical part of clinical practice.
 - B. In the treatment of most oral/odontogenic problems non-pharmacological intervention, i.e., primary dental care is more effective and a safer alternative to pharmacotherapy.
 - C. When pharmacotherapy is indicated practitioners must embrace patient demand.
 - D. Inappropriate overprescribing is a major concern in healthcare.
- 27. All of the following statements related to preventing ADRs are correct, EXCEPT for one. Which one is the exception?**
- A. Overprescribing does contribute to ADR risk, but not to antimicrobial resistance and opioid habituation.
 - B. The benefits should always outweigh the risks when a drug is prescribed.
 - C. Drug therapy should be individualized by taking into consideration both drug- and patient-related variables. Simple and clear oral instructions on how and when to take a drug should be given and reinforced by clear labeling and written instructions.
 - D. Patient-related factors that contribute to ADR risk include progressing age, the presence of multiple co-morbidities, living alone, and poor coping skills.
- 28. All of the following statements (steps) related to diagnosing ADRs are correct, EXCEPT for one. Which one is the exception?**
- A. Identify the drug(s) taken by the patient and verify that the onset of signs and symptoms was after the initiation of pharmacological intervention.
 - B. Determine the time-interval between the initiation of drug therapy and the onset of signs and symptoms.
 - C. Stop drug therapy and monitor signs and symptoms.
 - D. Once the ADR is resolved, it is good practice to restart drug therapy to confirm causality.
- 29. All of the following statements related to reporting ADRs are correct, EXCEPT for one. Which one is the exception?**
- A. The FDA launched MedWatch, an initiative designed to educate health care professional about the critical importance of being aware of, monitoring for, and reporting ADRs.
 - B. The reporting clinician is not responsible for proving causality; a suspected association constitutes sufficient reason to report.
 - C. The FDA holds the identity of the patient in strict confidence.
 - D. The reporting clinician's identity must be shared with the manufacturer of the drug.

- 30. All of the following statements related to the FDA's response to reports of ADRs are correct, EXCEPT for one. Which one is the exception?**
- A. The FDA may send out "Dear Health Professional" letters and require warning labels and/or changes to the packaging information (package insert).
 - B. The FDA may request further epidemiological investigations and/or manufacturer-sponsored post-marketing studies and conduct inspections of manufacturers' facilities and/or records.
 - C. The FDA may impose a financial penalty on the manufacturer.
 - D. The FDA may require withdrawal of the drug from the market.

References / Additional Resources

1. Conner MW, Dorian-Conner C, Vaidya VS, et al. Drug toxicity - Principles of pharmacology: The pathophysiologic basis of drug therapy, 4th edition. David E. Golan (Ed). Philadelphia, PA. Wolters Kluwer. 2017. 70-86.
2. Williams KA, Taifour ML, Huber MA. Adverse Drug Reactions - Part I. dentalcare.com. Accessed January 15, 2023.
3. Riedl MA, Casillas AM. Adverse drug reactions: types and treatment options. *Am Fam Physician*. 2003 Nov 1;68(9):1781-90.
4. Belle DJ, Singh H. Genetic factors in drug metabolism. *Am Fam Physician*. 2008 Jun 1;77(11):1553-60.
5. Dahlin A, Tantisira K. Pharmacogenomics - Principles of pharmacology: The pathophysiologic basis of drug therapy, 4th edition. David E. Golan (Ed). Philadelphia, PA. Wolters Kluwer. 2017. 87-95.
6. Krump NA, You J. Molecular mechanisms of viral oncogenesis in humans. *Nat Rev Microbiol*. 2018 Nov;16(11):684-698.
7. Valladares DA, Rasmussen SA. An update on teratogens for pediatric healthcare providers. *Curr Opin Pediatr*. 2022 Dec 1;34(6):565-571.
8. Council for International Organizations for Medical Sciences. Reporting adverse drug reactions. Definitions of terms and criteria for their use. Geneva. CIOMS. 2000. Accessed January 15, 2023
9. Roswarski M, Villa KR, Kiersma ME, et al. Prevalence of Adverse Drug Effects/Adverse Drug Reactions in 200 Most Commonly Prescribed Drugs Corrected for Prescription Volume. Purdue University, School of Pharmacy and Pharmaceutical Sciences, West Lafayette, IN. Accessed January 15, 2023.
10. National Institute of Health. U.S. National Library of Medicine. DailyMed. Accessed January 15, 2023.
11. Kumar K, Singh SI. Neuraxial opioid-induced pruritus: An update. *J Anaesthesiol Clin Pharmacol*. 2013 Jul-Sep; 29(3): 303-307. doi: 10.4103/0970-9185.117045
12. Radonjic-Hoesli S, Hofmeier KS, Micalletto S, et al. Urticaria and Angioedema: an Update on Classification and Pathogenesis. *Clin Rev Allergy Immunol*. 2018 Feb;54(1):88-101.
13. Fernandez J. Angioedema. Merck Manual Professional Version. Accessed January 15, 2023.
14. Samim F, Auluck A, Zed C, Williams PM. Erythema multiforme: a review of epidemiology, pathogenesis, clinical features, and treatment. *Dent Clin North Am*. 2013 Oct;57(4):583-96.
15. Jacobsen PL, Chávez EM. Clinical management of the dental patient taking multiple drugs. *J Contemp Dent Pract*. 2005 Nov 15;6(4):144-51.
16. Fernandez J. Overview of Allergic and Atopic Disorders. Merck Manual Professional Version. Accessed January 15, 2023.
17. Yuan A, Woo SB. Adverse drug events in the oral cavity. *Oral Surg Oral Med Oral Pathol Oral Radiol*. 2015 Jan;119(1):35-47.
18. Adwan MH. An update on drug-induced arthritis. *Rheumatol Int*. 2016 Aug;36(8):1089-97.
19. Rixe N, Tavarez MM. Serum Sickness. [Updated 2022 Aug 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Accessed January 15, 2023
20. Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. *N Engl J Med*. 2004 Dec 30;351(27):2827-31. Accessed January 15, 2023.
21. US National Library of Medicine. DailyMed. MINOCIN- minocycline hydrochloride capsule, coated pellets. Accessed January 15, 2023.
22. US National Library of Medicine. DailyMed. DOXYCYCLINE capsule. Accessed January 15, 2023.
23. Czeizel AE, Rockenbauer M. A population-based case-control teratologic study of oral oxytetracycline treatment during pregnancy. *Eur J Obstet Gynecol Reprod Biol*. 2000 Jan;88(1):27-33.

24. Alemany S, Avella-García C, Liew Z, et al. Prenatal and postnatal exposure to acetaminophen in relation to autism spectrum and attention-deficit and hyperactivity symptoms in childhood: Meta-analysis in six European population-based cohorts. *Eur J Epidemiol*. 2021 Oct;36(10):993-1004.
25. Baker BH, Lugo-Candelas C, Wu H, et al. Association of Prenatal Acetaminophen Exposure Measured in Meconium With Risk of Attention-Deficit/Hyperactivity Disorder Mediated by Frontoparietal Network Brain Connectivity. *JAMA Pediatr*. 2020 Nov 1;174(11):1073-1081.
26. Dosi TR, Chawla AK, Barkalle G, Phulambrikar T. Herpes zoster of orofacial region. *J Oral Maxillofac Pathol*. 2021 Sep-Dec;25(3):557.
27. Slots J, Saygun I, Sabeti M, Kubar A. Epstein-Barr virus in oral diseases. *J Periodontol Res*. 2006 Aug;41(4):235-44.
28. Scully C, Bagan JV. Adverse drug reactions in the orofacial region. *Crit Rev Oral Biol Med*. 2004 Jul 1;15(4):221-39.
29. American Addiction Centers. Drug Withdrawal Symptoms, Timelines & Treatment. Accessed January 15, 2023.
30. Lockhart PB, Tampi MP, Abt E, et al. Evidence-based clinical practice guideline on antibiotic use for the urgent management of pulpal- and periapical-related dental pain and intraoral swelling: A report from the American Dental Association. *J Am Dent Assoc*. 2019 Nov;150(11):906-921.
31. Scott IA, Le Couteur DG. Physicians need to take the lead in deprescribing. *Intern Med J*. 2015 Mar;45(3):352-6.
32. Stein K, Farmer J, Singhal S, et al. The use and misuse of antibiotics in dentistry: A scoping review. *J Am Dent Assoc*. 2018 Oct;149(10):869-884.
33. Thornhill MH, Suda KJ, Durkin MJ, Lockhart PB. Is it time US dentistry ended its opioid dependence? *J Am Dent Assoc*. 2019 Oct;150(10):883-889.
34. Tomczyk S, Whitten T, Holzbauer SM, Lynfield R. Combating antibiotic resistance: a survey on the antibiotic-prescribing habits of dentists. *Gen Dent*. 2018 Sep-Oct;66(5):61-68.
35. Davis TC, Federman AD, Bass PF 3rd, et al. Improving patient understanding of prescription drug label instructions. *J Gen Intern Med*. 2009 Jan;24(1):57-62.
36. National Academies of Sciences, Engineering, and Medicine. 2017. Communicating clearly about medicines: Proceedings of a workshop. Washington, DC: The National Academies Press. doi:
37. Sears K, Beigi P, Niyiyati SS, Egan R. Patient-Related Risk Factors for the Occurrence of Patient-Reported Medication Errors in One Community Pharmacy: A Local Perspective. *J Pharm Technol*. 2016 Feb;32(1):3-8.
38. U.S. Department of Health and Human Services. U.S. Food and Drug Administration. Safety. MedWatch. The FDA Safety Information and Adverse Event Reporting Program. Reporting Serious Problems to FDA. Instructions for Completing Form FDA 3500. Accessed January 15, 2023.

Additional Resources

No Additional Resources Available

About the Authors



Kristin A. Williams, DDS, MPH

Dr. Kristen A. Williams is an Assistant Professor, Department of Community Dentistry, and Assistant Dean for Admissions and Student Affairs at Case Western Reserve University, School of Dental Medicine in Cleveland, OH. Dr. Williams received her D.D.S. in 1989, completed a residency in Dental Public Health, and obtained a Master of Public Health in 2005, all at the School of Dental Medicine, Case Western Reserve University. Dr. Williams holds several positions in local professional societies, serves as a reviewer for national public health publications, published extensively in peer-reviewed journals, and presented many scientific programs at local, state and national professional meetings.

Email: kaw14@case.edu



M. Louay Taifour, BDS, DMD

Dr. Taifour earned his dental degree from Beirut Arab University School of Dental Medicine, then completed an AEGD residency and a Restorative Fellowship at Case Western Reserve School of Dental Medicine. Dr. Taifour teaches several pre-doctoral courses and is a full time clinical attending for the AEGD residency program.

Email: mohammedlouay.taifour@case.edu



Michael A. Huber, DDS

Adjunct Professor Department of Comprehensive Dentistry

UT Health San Antonio School of Dentistry, San Antonio, Texas

Dr. Michael A. Huber is an Adjunct Professor of Oral Medicine, Department of Comprehensive Dentistry, the UT Health School of Dentistry. He received his DDS from the UTHSCSA in 1980 and a Certificate in Oral Medicine from the National Naval Dental Center, Bethesda, Maryland in 1988. He is certified by the American Board of Oral Medicine. Dr. Huber served as Graduate Program Director in Oral Medicine at the National Naval Dental Center, Bethesda, Maryland. In addition, he served as Specialty Leader for Oral Medicine to the Surgeon General of the United States Navy, Washington, DC; and Force Dental Officer, Naval Air Force Atlantic, Norfolk, Virginia.

Since joining the faculty in 2002, Dr. Huber has been teaching both pre-doctoral and graduate dental students at the UT Health School of Dentistry. In 2019, he was awarded the University of Texas System Regents' Outstanding Teaching Award. He is a Past President of the American Academy of Oral Medicine and is a member of the dentalcare.com Advisory Board. Dr. Huber has spoken before many local, state, and national professional organizations. He has published over 90 journal articles, book chapters, and online postings.

Phone: (210) 567-3360

Fax: (210) 567-3334

Email: huberm@uthscsa.edu